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Abstract: Background: In free flap surgery, tissue is stored under hypothermic ischemia.
Extracorporeal perfusion (EP) has the potential to extend storage time and the tissue’s perspective of
survival. In the present study, the aim is to improve a recently established, simplified extracorporeal
perfusion system. Methods: Porcine musculus rectus abdominis were stored under different conditions.
One group was perfused continuously with a simplified one-way perfusion system for six hours,
while the other received only a single flush but no further treatment. A modified hydroxyethyl starch
solution was used as a perfusion and flushing solution. Vitality, functionality, and metabolic activity
of both groups were analyzed. Results: Perfused muscles, in contrast to the ischemically stored
ones, showed no loss of vitality and significantly less functionality loss, confirming the superiority of
storage under continuous perfusion over ischemic storage. Furthermore, in comparison to a previous
study, the results were improved even further by using a modified hydroxyethyl starch solution.
Conclusion: The use of EP has major benefits compared to the clinical standard static storage at room
temperature. Continuous perfusion not only maintains the oxygen and nutrient supply but also
removes toxic metabolites formed due to inadequate storage conditions.
Keywords: hydroxyethyl starch solution; perfusion solution; extracorporeal perfusion; ischemia;
free flap transfer
1. Introduction
Preventing ischemia-related cell damage is a key challenge when preserving tissue extracorporeally
for transplantation or replantation [1–4]. Presently, ischemically stored tissue is routinely kept under
hypothermia to postpone ischemic damage [5] but the tissue’s time of survival is still very limited,
especially if muscle tissue is involved [6]. Although in reconstructive surgery, a prolonged time
of ischemia of free flaps is uncommon, any method that reduces even early ischemia-related cell
damage is highly advantageous. This is particularly true in cases of reimplantation of amputates [7,8].
Even short-term exposure to ischemia can threaten the surgery’s success since it can result in effects
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like the “no reflow phenomenon” or “ischemia–reperfusion syndrome”, with the severity of these
incidents being in direct correlation to the time of the preceding ischemia [9–11].
Extracorporeal perfusion (EP) has the potential to substantially increase the time of survival of
tissue disconnected from blood circulation [12–27]. This is especially true in the case of major amputates
since the separated limb contains a lot of muscle tissue that is very sensitive to ischemia, limiting the
time of survival to 4 h [6]. In two clinical cases, we were able to perform a reconnection of amputated
limbs after 12 and 15 h of extracorporeal storage. In these cases, an immediate replantation was not
possible due to the patients’ critical medical condition. EP helped to bridge the time until both patients
were stable enough for replantation. In these cases, we did not have to follow the principle of “life
before limb” but were able to maintain both life and limb. [25]. Nonetheless, it still has no relevance in
daily clinical routine [28]. One of the reasons is the high cost-to-benefit ratio. Most EP systems consist
of a complex technical setup and demand a high level of expertise. To make EP a simple, cost-effective,
yet powerful tool in cases of free flap transfer, we recently introduced a simplified EP system [24,27].
By omitting pumps and all forms of perfusate renewal, the perfusate is merely drained into the muscle
from an infusion bag, while the outflow is discarded. We were able to demonstrate that the conservation
of free muscle tissue in this system is comparable to a complex perfusion system with pump-mediated
flow rate control and perfusate regeneration. The functionality and viability of perfused muscles using
both EP systems show similar results, and they are both superior to ischemically stored muscles [24,27].
Nevertheless, there is still room for improvement, mainly the extension of the maximum time of
storage. In the present study, we improved pre-existing results by modifying the perfusion solution.
A colloidal solution was chosen to reduce edema formation, one of the major drawbacks of EP with
acellular perfusion solutions [23,24,26,27,29]. The solution was then modified to improve the maximum
storage time.
2. Methods
2.1. Animals, Surgical Protocol, and Experimental Setup
Animals (mature male pigs, n = 5; Erzeugergemeinschaft Franken Schwaben, Tierische Veredelung,
Wertingen-Geratshofen, Wertingen, Germany) were treated identically to previous studies [22–24,26].
The surgical procedure was performed by a plastic surgeon, while anesthesia and viability parameter
observation were conducted by a veterinarian. The detailed surgical method has already been
published [22–24,26]. In short, the anterior rectus sheath was opened after a longitudinal incision
over both rectus abdominis muscles in a supine position. The muscles were then dissected step
by step from the anterior and posterior rectus leaf, and the deep inferior epigastric pedicle was
dissected caudally as a pedicle vessel. At the end, a classical free rectus abdominis muscle flap
was harvested bilaterally. All experiments were approved by the Government of Mittelfranken,
Germany (No. 65-2532.2-65 1/10), and the Animal Care Committee of the Friedrich-Alexander
University, Erlangen-Nürnberg. All experiments were carried out according to the relevant guidelines
and regulations.
Both rectus abdominis muscles were used in the perfusion experiments. After the surgical procedure,
the caudal segment of both muscles was cut between the third and fourth intersection, with the deep
inferior epigastric pedicle accessible for cannulation (arterial: 22 G, di = 0.9 mm, l = 25 mm; venous:
18 G, di = 1.3 mm, l = 45 mm). Both muscles were flushed with 20 mL of perfusate (see Table 1) prior to
storage experiments to remove intravasal blood residues, approx. 20 min before experiment initiation.
One muscle was perfused continuously for six hours, while the other muscle did not receive any
further treatment for the same duration (ischemic storage) at room temperature.
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The perfusion solution was modified to improve storage conditions and, thus, increase the
maximum storage time. A colloidal solution (Volulyte 6%®, Fresenius Kabi, Bad Homburg, Germany)
was chosen as the base solution. Glucose (5 mmol/L) and calcium phosphate (2.3 mmol/L) were added
to adjust the concentration to a physiological level, with the aim of enhancing the muscles’ ability to
contract. Heparin (5000 IU/L) was administered to prevent the clotting of possible blood residues, and
the pH was adjusted to a physiological level of 7.4.
Both muscles, perfused and ischemic, were clamped at the proximal end to the bottom of the EP
system and connected to a force gauge unit by their distal end (see Figure 1). The muscles were then
submersed independently in separate electrolyte solution (based on the composition of Jonosteril®)
basins at room temperature. Oxygen consumption of the perfused muscle was calculated by continuous
measurement of the perfusate’s arterial and venous oxygen content.
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2.2. Extracorporeal Perfusion Parameters and Functionality Monitoring
The functionality of isolated muscle tissue is evaluated by its ability to exert force as a response to
external electric field stimulation (EFS) [22]. This impulse is transmitted by two silver plate electrodes,
placed at equal distance on each planar side of the muscle, and the electrolyte solution. The electrodes
J. Clin. Med. 2020, 9, 3929 4 of 11
are connected to an external muscle stimulator, which generates a monopolar pulsatile square wave
current (frequency 100 Hz, pulse width 1 ms). EFS is conducted every 15 min, with three measurements
in direct sequence, each with an individual duration of 10 s; the resulting muscle force is then recorded.
Muscles are initially stimulated with 0.5 V. Due to the detrimental effects of muscle damage or muscle
exhaustion, the muscles’ forces decline over the duration of storage. To compensate for this decrease,
the voltage is increased in steps of 0.5 V when the resulting force drops below a threshold of 0.25 N.
Stimulating the muscles initially with a high voltage results in severe tissue damage.
The muscles’ forces are recorded with a force gauge connected to the muscles’ cranial end.
Two resulting force levels can be observed over the ten-second measurement: a maximum force Fmax,
which declines into a plateau over the recorded 10 s into a steady force Fsteady. The maximum force
Fmax serves as an indicator for an intact excitation-contraction coupling, while the steady force Fsteady
shows the muscle’s fatigue during ongoing stimulation [29].
To compare the forces from different muscles and to compensate for the increasing stimulation
voltage, the forces F are normalized with reference to the stimulation voltage Ustim. Furthermore,





The resulting effective forces (Feff,max and Feff,steady) are plotted over the time of storage in the
results. Effective force points were fitted with an exponential decay curve (using Sigma Plot v11.0
software, Systat Software, Inc., Berkshire, UK) to calculate the force decline rates (µ) as a comparative
value for muscles under different storage conditions.
Feff = a·e−µt
The resulting force decline rates (µ) and coefficients of determination (Rsqr) are summarized in
the results.
2.3. Histology and Immunohistochemistry
Apart from force recordings, immunohistochemically stained histological samples were used
to evaluate storage impact on cellular viability. Histological tissue sampling was reduced to two
points in time, before and after extracorporeal storage, since tissue sampling affects perfusion and EFS
measurements due to the injury of muscle fibers and blood vessels. The first sample was taken at the
time of tissue harvest; the second was taken after six hours of storage.
All biopsies were fixed in 4% buffered formalin for 24 h and subsequently embedded in paraffin.
The tissue’s viability was determined by the number of apoptotic cell nuclei highlighted with annexin V.
Staining was performed using an anti-annexin V antibody (ab14196; Abcam, Cambridge, UK). The tissue
samples, embedded in paraffin, were processed, cut, and stained according to previously published
detailed protocol [22]. The slides were subsequently digitized (Panoramic-Midi and Panoramic Flash
250, 3D-Histech AG, Budapest, Hungary) to allow a standardized protocol for identifying the ratio of
annexin-V-positive myonuclei to the total number of myonuclei: Φapoptotic.
2.4. Perfusate Analysis
To evaluate the effectiveness of EP for muscle conservation, blood gas analysis (ABL800 Flex,
Radiometer RSCH GmbH) was performed using venous perfusate samples. Glucose uptake,
lactate formation, and the resulting changes in pH value, as well as potassium leakage, which indicates
cell damage, were analyzed.
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2.5. Statistical Analysis
A two-way analysis of variance (ANOVA) was carried out (with posthoc Holm–Sidak analysis)
for values of Feff with respect to the factor treatments (perfused, ischemic) and storage time using
v11.0 Sigma Plot software (Systat Software, Inc.). For statistical analysis of Φapoptotic of perfused and
ischemic muscles, a two-way analysis of variance (ANOVA) was carried out using the same software.
3. Results
With a fixed hydrostatic pressure of approx. 10 kPa, stable continuous perfusion of all muscles
can be achieved, with an average perfusate flow rate of 0.70 (±0.23) mL/min. Oxygen consumption,
calculated from the arterial and venous oxygen content of the perfusate solution (see Figure 2),
the perfusion rate, and the muscles’ weight were within a physiological range, between 0.09 and
0.14 mLO2/min−1/kg−1. The perfused muscles developed interstitial edema during storage, resulting in
an average weight increase of 49.4% (±5.9%). By definition, the ischemic muscles did not receive any
form of perfusion and were, therefore, considered to be anoxic. Furthermore, they did not develop
any edema.
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Figure 2. Oxygen content in % of the saturation concentration of the arterial (gray lines) and venous
(black lines) perfusate.
All perfused muscles presented a significantly higher rate of functionality compared to the
ischemically stored muscles. While all perfused muscles were able to exert a force response after
EFS, the ischemic muscles failed to do so between 3.5 and 5.25 h of ischemia. This behavior was also
reflected by the force decline rates (µ) of the effective forces Fmax and Fsteady (see Figure 3). While the
effective forces of perfused muscles declined with the rates of µmax = 0.38 h−1 and µsteady = 0.48 h−1,
the forces of the ischemic muscle declined faster, with rates of µmax = 1.30 h−1 and µsteady = 1.56 h−1.
Furthermore, the differences between the effective forces of both perfused and ischemic muscles were
statistically significant up to 3.25 h of storage for Fmax (p = 0.027) and 2.25 h for Fsteady (p = 0.038).
Apart from improved functionality, the perfused muscles also presented higher cellular viability.
All samples of the ischemically stored muscles showed a statistically significant increase in ∆Φapoptotic
= 26% after 6 h, indicating progressing apoptosis (see Figure 4). For all muscle samples of the perfused
group, no significant increase in annexin-V-positive nuclei was observed after six hours, with an
average increase of ∆Φapoptotic = 2.7%.
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Perfusat analysis also confir ed that the perfused mu cle was metaboli lly active, as, for example,
glucose was consumed, but it also i icated that the tissue’s cells were under stress. The pH decreased
due t formation of lactate, and an accumulatio of interst tial potas ium can be identified
(see Figure 5). The data poi ts at t = 0 h correspon to the composition of the perfusate (see Table 1).
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After six hours of perfusion, the pH of the perfusate dropped to a final value of 6.2 (±0.1). The glucose
concentration dropped in the first two hours to a value of 4.1 (±0.4) mmol/L but slowly increased
again to 4.4 (±0.5) mmol/L after six hours. Potassium concentration increased to a maximum of
6.1 (±0.5) mmol/L after 5 h of EP. After six hours, the potassium level was slightly decreased to a
concentration of 5.7 (±0.6) mmol/L.
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4. Discussion
Our intention is to develop a simple, cost-effective, and easily applicable perfusion system for the
storage of free flaps and to make the benefits of this novel technique easily accessible in the clinical
routine. In the present study, our aim is to improve our previously published method of a simple
unidirectional EP [24] by using a modified perfusion solution.
The results indicate that EP is superior to ischemic storage. Perfused muscles show increased
levels of vitality and functionality. While ischemically stored muscles show significant levels of
apoptotic cells, perfused muscles do not. Furthermore, by extrapolating and comparing the force
decline rates, perfused muscles, flushed with the modified starch solution, are functional up to 3.5 times
longer than the ischemically stored ones. When compared to muscles stored using the common clinical
standard static storage at room temperature after a flush with Jonosteril® [22], the functionality can be
preserved approximately 11 times longer with EP. This finding further stresses the importance of the
storage solution.
The efficacy of EP as a tool to prevent ischemia-related cell damage in case of free flap surgery, as
well as limb amputations, has been shown in several experimental approaches. Müller et al. were
able to successfully reimplant porcine forelimbs after a period of 12 h of EP [20]. Wolff et al. (2016)
described a series of three cases using whole blood for EP to achieve a free flap transfer without vascular
anastomosis [30]. Hereby, EP was performed as a bridge until autonomization of the flaps occurred,
and the flaps became independent from the external blood supply. However, using unidirectional
perfusion requires a high amount of the patient’s blood. According to Wolff et al. (2016), EP was
necessary for a successful free flap transfer since vessel-depleted necks left no possibility for vascular
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anastomosis. Being a well-established technique, even in the case of lower limb reconstruction with
long distances [31–34], it is our opinion that it is implausible that the use of vascular loops or vein
grafts in a neck reconstruction with very short distances would not be favorable to unidirectional EP
with whole-blood.
The idea behind using blood as a perfusate for EP is obvious: the composition is inherently
physiological, it provides physiological oncotic pressure, and it contains erythrocytes that increase
the oxygen content of the perfusate. Nonetheless, studies using blood have reported lactate
formation during EP as well, indicating oxygen deficiency [18,35,36]. Apart from the reported lactate
formation, using blood as perfusate has some major disadvantages. First, blood availability is highly
limited. Second, Fichter et al. (2016) suggested that the two major drawbacks of using blood as a perfusate
are hemolysis and hemostasis [15], which can lead to the no reflow phenomenon. In preliminary
experiments, perfusion with blood did not improve the outcome of EP [13]. Furthermore, in ischemic
muscles, residual blood was still present even after flushing with perfusate. This supports the
use of continuous perfusion without erythrocytes to avoid blood clotting and a subsequent
“no reflow” phenomenon.
A promising approach was recently published by Kueckelhaus et al. (2017) using an acellular
EP solution to preserve the forelimbs of pigs for a time period of 12 h, followed by heterotopic
reimplantation [17]. EP perfusion was performed in a circuit using perfusate regeneration. This increases
the complexity of the perfusion setup by including pumps, oxygenators, and bacterial filters to avoid
contamination of the tissue, thus increasing equipment requirements and, consequently, time and
investment. The resulting costs and efforts can render a complex EP system unfeasible. Slater et al. (2016)
stated that the cost-to-benefit ratio is of major importance. The devices need to be small and mobile;
otherwise, EP will not move into the clinical routine [28].
However, when using a unidirectional perfusion system without perfusate recycling, the amount
of perfusate needed for continuous perfusion is not negligible. Nonetheless, discarding the venous
perfusate provides an additional major advantage in that harmful metabolites, which accumulate in the
perfusate during EP, are flushed out and not reintroduced into the tissue. With this in mind, removal of
the perfusate is preferable to perfusate regeneration. Consequently, in our studies, only inexpensive
perfusate solutions, which are nearly unlimitedly available, are used (Jonosteril® and Volulyte®).
In conclusion, the use of EP has major benefits compared to the clinical standard static storage
at room temperature. As a limitation, it has to be mentioned that although the flaps of our control
group were kept under hypothermic conditions (i.e., room temperature), we have no data regarding
perfusion with active cooling.
Continuous perfusion not only maintains oxygen and nutrient supply, if added, but also removes
toxic metabolites caused by inadequate storage conditions. Therefore, even during short-term storage
of muscle tissue below the critical ischemic time, EP helps to minimize the risk of ischemia-reperfusion
damage and associated effects such as hemostasis. Even with a slight risk of edema-related complications,
the consequences of ischemia-related damage are, by far, worse. The simplicity of the presented
perfusion system, an infusion bag connected to a cannula, also allows for immediate application
without special equipment or training. Despite these promising results, it should be noted that the
necessity of extracorporeal perfusion is very rare and reserved for specific clinical scenarios.
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